Subgroups
Bayer HealthCare
-
Friday - January 27, 2012
Not intended for U.S. and UK media - Indication extension for contrast medium
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older » more
-
Thursday - January 19, 2012
Bayer HealthCare Expands Research and Manufacturing Capabilities for Interventional Franchise » more
-
Wednesday - January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation » more
-
Wednesday - January 18, 2012
Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
First presentation of data from CORRECT trial as “Late Breaking Abstract” at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) » more
-
Tuesday - January 10, 2012
Not intended for US Media: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 » more
-
Monday - January 9, 2012
Bayer HealthCare to Share Lab Space with Start-Up Companies
Dedicated lab space-model at Bayer HealthCare U.S. Innovation Center to be called CoLaborator™ / Shared lab space will help promising life science companies get their start » more
-
Thursday - December 29, 2011
Not intended for U.S. and UK Media - Submission in New Indication:
Bayer’s Xarelto® (Rivaroxaban) Submitted for U.S. Marketing Authorisation to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome » more
-
Thursday - December 22, 2011
Not intended for U.S. and UK media: Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy » more
-
Tuesday - December 20, 2011
Not intended for U.S. and UK media: Clear commitment to innovation
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again » more
-
Tuesday - December 20, 2011
Chris Southwell participates in the world’s most famous triathlon:
Going to great lengths
Professional snowboarder and type 1 diabetic explores his limits at the Iron Man » more
-
Monday - December 19, 2011
For use outside the US and UK only
Bayer’s Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT
In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT and the prevention of recurrent DVT and PE, Xarelto is the first oral anticoagulant to offer patients both efficacy and the convenience of a single-drug solution, without the need for injections or monitoring / Xarelto is now approved in the EU across three indications in the area of venous and arterial thromboembolism (VAT) » more
-
Wednesday - December 14, 2011
For use outside the US and UK only
New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.
Once approved, the new low dose IUS will offer young women contraception for up to three years » more
-
Friday - December 9, 2011
Not intended for U.S. and UK media: Bayer’s drospirenone-containing combination oral contraceptives:
FDA Advisory Committees affirm positive benefit-risk profile and recommend an update of US labels to reflect information from available studies » more
-
Monday - December 5, 2011
First outcome study with Bayer’s Contour USB started
Integrated diabetes software for behavioral changes and improved glycemic control
Transforming blood glucose data into meaningful insights » more
-
Monday - December 5, 2011
International Diabetes Federation starts programme:
Young leaders to raise awareness of diabetes
Bayer HealthCare supports the IDF Young Leaders in Diabetes Programme » more
-
Monday - November 28, 2011
Not intended for U.S. and UK Media
Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in China » more
-
Friday - November 25, 2011
8th Bayer HealthCare European Diabetes Nurses Symposium:
Education can significantly improve glycaemic control
British team awarded for providing a structured pathway to reduce HbA1c levels » more
-
Tuesday - November 22, 2011
Bayer HealthCare and the Association of German Medical Journalists honor outstanding medical journalism for the ninth time
2010 European Journalists' Prize goes to Dr. Britta Julia Dombrowe and John A. Kantara » more
-
Friday - November 18, 2011
Not intended for U.S. and UK Media
U.S. FDA Approves EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Approval based on positive results of VIEW 1 and VIEW 2 clinical trials / Regeneron Pharmaceuticals will market EYLEA™ in the U.S. » more
-
Thursday - November 17, 2011
New edition of research, the Bayer scientific magazine
Innovations from the world of research at Bayer
Personalized medicine against cancer / Creating new active crop protection ingredients with biotechnology / Electric mobility: materials for the cars of the future » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
